Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

2상 완료 NCT05834738

요약

The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).

Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12

From Baseline to Week 12 · percentage change in UPCR

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
• Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
• Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
• High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida

전체 임상